The IIT-CII Center would work on mathematical prediction models based on health data that would help minimize the impact of infectious diseases.

The Confederation of Indian Industry (CII) and the Indian Institute of Technology Kanpur have teamed up to launch IIT Kanpur – CII Risk Surveillance Center to monitor and control the spread of Covid-19 and other similar infections in the future.

IIT Kanpur director Abhay Karandikar said better risk monitoring was the reason for effectively dealing with the pandemic in other parts of the world.

The IIT-CII Center would work on mathematical prediction models based on health data that would help minimize the impact of infectious diseases. It would help understand the transmission of infections and identify the risk factors involved.

The CII Foundation will implement the project with support from Jubilant FoodWorks, Jubilant Foundation, DCM Shriram Foundation, National Engineering Industries and CESC. Hari S Bhartia, chair of the CII Task Force on Risk Surveillance, and co-chair and director, Jubilant Pharmova, said the virus knew no boundaries, so sharing data at every level and angle was necessary to be better prepared. are on endemics and pandemics.

Randeep Guleria, Chairman of the CII Public Health Council and Director, AIIMS Delhi, said forecasting models were needed so that timely action could be taken. Suchitra Ella, deputy chair, CII Southern Region, and joint MD, Bharat Biotech, said collaboration with institutions and public health foundations in regions and countries would strengthen the ability to predict, monitor and manage infectious diseases. Vaccine research and product development rely heavily on information about the disease and its spread, Ella said.


This post IIT Kanpur partners with CII to establish risk monitoring center for Covid-19 and other infectious diseases was original published at “https://www.financialexpress.com/lifestyle/health/iit-kanpur-ties-up-with-cii-to-set-up-risk-surveillance-centre-for-covid-19-other-infectious-diseases/2462280/”

LEAVE A REPLY

Please enter your comment!
Please enter your name here